Renewed funding for GENVABO, an oral medicine PhD project

20 December 2013


Having supported the UCL Eastman Dental Institute led GENVABO project for three years, the Inman Charity is pleased with its outstanding progress and has agreed to renew its funding, worth £20,000 in total.

GENVABO refers to Genetic Variants as Biomarkers of Jaw Osteonecrosis associated with Bisphosphonates. It is led by the UCL Eastman Dental Institute, and collaborators include the International Serious Adverse Event Consortium (iSAEC) in the US and over 20 research centres from Austria, Italy, Spain, Sweden and the UK.

It is a genomewide association study (GWAS) which aims at identifying single nucleotide polymorphisms (SNPs) for jawbone death, a potentially severe drug side-effect of bisphosphonates. Compared to previous GWAS, GENVABO has the largest cohort of participants and is also the first group to have identified a genomewide significant SNP, which can contribute towards personalised medicine and better understanding of the disease in future.

GENVABO’s second phase study will involve validating results from the first phase through replicating the GWAS in a new cohort of comparable phenotype.

Dr Stefano Fedele and Professor Stephen Porter are the leads of GENVABO and the PhD student is Dr Polly Pok-Lam Fung. In addition to funding from the Inman Charity, Dr Fung also received a UCL Grand Challenge Studentship and a UCL Overseas Research Scholarship to support her study.

Find out more about research at UCL Eastman Dental Institute